4 Diffuse Large B-Cell Lymphoma Clinical Trials in San Francisco, CA (2026)

Q: How do I join a clinical trial in San Francisco?

Browse available studies, click one that interests you, and complete the free eligibility form. A study coordinator at the San Francisco research site will contact you.

Recruiting Diffuse Large B-Cell Lymphoma Studies in San Francisco

NCT06717347Recruiting

A Study to Evaluate Zilovertamab Vedotin (MK-2140) Combination With Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Participants With Previously Untreated DLBCL (MK-2140-010)

The purpose of this study is to evaluate if zilovertamab vedotin with standard treatment can help people live longer without the cancer growing or spreading than people who receive standard treatment ...

San Francisco, CAPHASE31,046 participantsMerck Sharp & Dohme LLC

View Study Details

NCT05633615Recruiting

Testing Drug Treatments After CAR T-cell Therapy in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma

This phase II trial tests whether mosunetuzumab and/or polatuzumab vedotin helps benefit patients who have received chemotherapy (fludarabine and cyclophosphamide) followed by chimeric antigen recepto...

San Francisco, CAPHASE2396 participantsSWOG Cancer Research Network

View Study Details

NCT06500273Recruiting

Consolidation of First-Line MRD+ Remission With Cema-cel in Patients With LBCL

This is a randomized, open-label study in adult patients who have completed standard first line therapy for large B-cell lymphoma (LBCL) and achieved a complete response or partial response suitable f...

San Francisco, CAPHASE2250 participantsAllogene Therapeutics

View Study Details

NCT06806033Recruiting

A Study to Evaluate the Optimization of the Cytokine Release Syndrome Profile for Glofitamab in Combination With Gemcitabine Plus Oxaliplatin in Participants With Relapsed/Refractory Diffuse Large B-Cell Lymphoma

The main goal of this trial is to study the frequency and severity of cytokine release syndrome (CRS) in participants with diffuse large B-cell lymphoma (DLBCL) who are using a combination of glofitam...

San Francisco, CAPHASE2130 participantsHoffmann-La Roche

View Study Details

About Diffuse Large B-Cell Lymphoma Clinical Trials in San Francisco

Diffuse large B-cell lymphoma (DLBCL) is the most common type of non-Hodgkin lymphoma, accounting for about 30% of cases. It is an aggressive lymphoma that grows rapidly. Treatment usually involves chemoimmunotherapy, with CAR-T cell therapy for relapsed cases.

There are currently 4 diffuse large b-cell lymphoma clinical trials recruiting participants in San Francisco, CA. These studies are seeking a combined 1,822 participants. Research is being sponsored by Merck Sharp & Dohme LLC, SWOG Cancer Research Network, Allogene Therapeutics and 1 other organizations. Clinical trial participation is free and participants receive study-related medical care at no cost.

Diffuse Large B-Cell Lymphoma Clinical Trials in San Francisco — FAQ

Are there diffuse large b-cell lymphoma clinical trials in San Francisco?

Yes, there are 4 diffuse large b-cell lymphoma clinical trials currently recruiting in San Francisco, CA. Browse the studies on this page to find one that fits.

How do I join a clinical trial in San Francisco?

Browse the studies listed above, click one that interests you, and complete the free eligibility form. A study coordinator at the San Francisco research site will contact you about next steps.

Are clinical trials in San Francisco free?

Yes, clinical trial participation is always free. Study-related treatment, medical tests, and doctor visits are provided at no cost. Many San Francisco studies also compensate for your time and travel.

What diffuse large b-cell lymphoma treatments are being tested?

The 4 active trials in San Francisco are testing new therapies including novel drugs, biologics, and treatment approaches for diffuse large b-cell lymphoma.

Data updated October 16, 2026 from ClinicalTrials.gov